false
0001996192
0001996192
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
November 17, 2026
Quanome Technologies, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Nevada |
|
001-42140 |
|
82-1978491 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
112 W 34th St, FL 18, Room 18022
New York, NY |
|
10120 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (778) 888-7232
Not Applicable
(Former name or former address if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
| Common Stock, $0.0001 par value per share |
|
QNME |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On November 17, 2026, the Company issued a press
release titled “Quanome Reports Fiscal First-Quarter Results: First quarter establishes foundation for first enterprise customer
agreement and US$13.5 million prepayment for dedicated AI inference services.” A copy of the press release is furnished herewith
as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number |
|
Description |
| 99.1 |
|
Press release, issued on November 17, 2026 |
| 104 |
|
Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Quanome Technologies, Inc. |
| |
|
| Dated: November 17, 2026 |
By: |
/s/ Yang Li |
| |
Name: |
Yang Li |
| |
Title: |
Chief Executive Officer and Director |
Exhibit 99.1
Quanome Reports Fiscal First-Quarter Results
First quarter establishes foundation for first
enterprise customer agreement
and US$13.5 million prepayment for dedicated
AI inference services
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) --
Quanome Technologies, Inc. (Nasdaq: QNME, “Quanome”) today reported results for the fiscal first quarter ended September
30, 2026, and provided an update on its AI computing business. During the quarter, Quanome entered into an approximately US$18.8 million
agreement to purchase 32 NVIDIA-powered GPU servers for the first U.S. AI inference hub of XDT Infrastructure I, LLC (“XDT”),
its indirect wholly owned subsidiary.
“This first quarter represents a critical
milestone in the launch of Quanome as a business focused on quantum and AI opportunities,” commented Mr. Yang Li, Chief Executive
Officer of Quanome Technologies. “Our business pivot led to our first enterprise customer agreement, with an initial order commitment
exceeding US$100 million over a five-year term, subject to contractual service-start conditions. Following quarter-end, we received a
US$13.5 million prepayment toward future services. It is important for shareholders to recognize the momentum we established in the first
quarter that is now supporting our progress toward service commencement.”
Results of Operations & Operational Update
Quanome’s established pharmaceutical distribution
business, Hupan Pharmaceutical (Hubei) Co., Ltd (“Hupan Pharmaceutical,” and, together with Quanome, XDT and Quanome’s
other subsidiaries, the “Group”), continued to provide the Group’s revenue base as XDT prepared to launch services.
Quarterly revenue increased 53% year over year to US$2.05 million. Gross profit doubled to US$1.10 million, primarily reflecting higher
supplier rebates.
XDT remained pre-revenue at quarter-end. The hub
is designed to give enterprise customers dedicated capacity to run AI models on infrastructure that the Group owns and operates.
Following quarter-end, Quanome announced further
developments across its quantum and AI strategy. During the first quarter of fiscal 2027, XDT secured its first enterprise customer agreement
and subsequently received, on October 29, 2026, a US$13.5 million prepayment toward future services. The initial order has a total commitment
value exceeding US$100 million over a 60-month term that begins on the service-ready date, subject to contractual service-start conditions.
Separately, Quanome also agreed to purchase a further 32 GPU servers on September 29, 2026, bringing the total under purchase agreements
to 64.
Management anticipates initial service revenue
from Quanome’s subsidiary, XDT, to commence in the second or third quarter of fiscal 2027, subject to successful deployment and
satisfaction of the service-start conditions. XDT is the commercial focus of Quanome’s Quantum and AI Systems stream.
On November 9, 2026, Quanome announced advancements
within its Quantum Life Sciences – Molecular Discovery stream, reporting an all-stock agreement to acquire approximately
5% of QAI Labs at closing. QAI Labs is an independent life sciences technology company developing NOVA-3, a platform that combines AI-assisted
molecular design with laboratory testing to identify antibodies that could be developed into treatments for disease.
Advanced Nuclear and Quantum-Safe Cybersecurity
complete Quanome’s four strategic areas of focus, through which the Company aims to build long-term growth and shareholder value.
Ends.
Forward-looking statements
This release contains forward-looking statements.
Statements about infrastructure deployment, service commencement, expected revenue timing, completion of the QAI Labs investment and long-term
growth reflect management’s current expectations. Actual outcomes may differ materially depending on equipment delivery, satisfaction
of contractual conditions, customer and supplier performance, financing availability and other risks described in Quanome’s most
recent Annual Report on Form 10-K for the fiscal year ended June 30, 2026 and any subsequent documents filed with the U.S. Securities
and Exchange Commission.
About Quanome
Quanome Technologies, Inc. (Nasdaq: QNME) is a
U.S.-based company headquartered in New York, New York. Quanome is building capabilities and an investment portfolio at the intersection
of quantum technologies, artificial intelligence, advanced simulation and intelligent systems. Through internal development, strategic
relationships and selected investments, Quanome seeks to translate emerging science into real-world applications across life sciences,
cybersecurity, advanced materials, energy, financial systems and other industries shaped by complex computational challenges. For more
information, visit www.quanometech.com.
Media and investor contact
Lauren Callie | investor@quanometech.com